Nektar Therapeutics' announcement of one-year extension data for rezpegaldesleukin (rezpeg) in severe alopecia areata represents more than incremental progress—it may signal a fundamental shift in treating autoimmune hair loss. The STAT News report by Adam Feuerstein highlights that 27% of participants on either low or high dose achieved a SALT score of 20 or better (≥80% scalp hair coverage) after 12 months. While this matches or exceeds outcomes seen with low-dose Olumiant (baricitinib), the original coverage underplays critical context around study design, mechanism, and the broader therapeutic landscape.

This was an open-label extension following an earlier randomized segment, not a fresh placebo-controlled RCT. Exact sample size for the extension cohort was not disclosed in the release, limiting interpretability; such extensions often suffer from attrition bias and lack the rigor of the pivotal phase 3 BARRIER trials for baricitinib (two RCTs, n=1,200+ combined, published in NEJM 2022). Those Lilly trials demonstrated 35-39% SALT-20 response at 36 weeks with 4mg daily dosing, but real-world persistence is challenged by safety warnings—including serious infections, malignancy, thrombosis, and a boxed warning that constrains physician prescribing.

What the STAT coverage largely missed is rezpeg's differentiated biology. Unlike JAK inhibitors that broadly block cytokine signaling downstream of multiple inflammatory pathways, rezpeg is a pegylated IL-2 conjugate designed to selectively stimulate regulatory T cells (Tregs). By restoring Treg/effector T-cell balance rather than globally dampening immunity, it offers a theoretically safer profile for chronic use. This aligns with emerging patterns in autoimmune disease research: see the 2023 Journal of Clinical Investigation review on low-dose IL-2 therapies in lupus and type 1 diabetes, which showed Treg expansion with minimal broad immunosuppression (observational and early-phase data, n<150 across studies, no major pharma conflicts declared).

Alopecia areata affects approximately 2.1% of the global population at some point, with severe forms causing profound psychosocial burden. Current non-steroidal options remain scarce; topical and intralesional steroids carry atrophy risks, while JAK inhibitors, though transformative for many, require chronic administration with cumulative safety tolls. Rezpeg's durability signal at one year—maintained or improved responses without steroids—is therefore noteworthy, especially as most alopecia therapies see waning efficacy over time due to tachyphylaxis or disease rebound.

Conflicts must be noted: Nektar funded and analyzed the data; independent peer-reviewed publication of the full dataset will be essential. Head-to-head trials are absent, and 27% success still leaves most patients without adequate response, underscoring the heterogeneous nature of autoimmune hair loss. Yet the mechanistic elegance—targeting the root immune dysregulation rather than downstream inflammation—connects to parallel advances in vitiligo (where JAK inhibitors gained approval) and atopic dermatitis, where Nektar is also studying rezpeg.

If phase 3 confirms these findings in larger, more diverse cohorts, rezpeg could establish a new paradigm: durable, non-steroidal immunomodulation for alopecia areata and potentially other Treg-defective autoimmune conditions. The field has waited decades for options beyond steroids and crude immunosuppressants; this approach, grounded in restoring immune homeostasis, may finally deliver on that promise.